Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy

Boyd R. Viers, Stephen A. Boorjian, Igor Frank, Robert F. Tarrell, Prabin Thapa, Robert Jeffrey Karnes, R. Houston Thompson, Matthew K. Tollefson

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Background Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation that has been associated with adverse survival in a variety of malignancies. However, the relationship between NLR and oncologic outcomes following radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) has not been well studied.

Design, setting, and participants We identified 899 patients who underwent RC without neoadjuvant therapy at our institution between 1994 and 2005 and who had a pretreatment NLR.

Outcome measurements and statistical analysis Preoperative NLR (within 90 d prior to RC) was recorded. Recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard and logistic regression models were used to analyze the association of NLR with clinicopathologic outcomes.

Results and limitations Median postoperative follow-up was 10.9 yr (interquartile range: 8.3-13.9 yr). Higher preoperative NLR was associated with significantly increased risks of pathologic, extravesical tumor extension (odds ratio [OR]: 1.07; p = 0.03) and lymph node involvement (OR: 1.09; p = 0.02). Univariately, 10-yr cancer-specific survival was significantly worse among patients with a preoperative NLR (≥2.7 [51%] vs <2.7 [64%]; p < 0.001). Moreover, on multivariate analysis, increased preoperative NLR was independently associated with greater risks of disease recurrence (hazard ratio [HR]: 1.04; p = 0.02), death from bladder cancer (HR: 1.04; p = 0.01), and all-cause mortality (HR: 1.03; p = 0.01).

Conclusions Elevated preoperative NLR among patients undergoing RC is associated with significantly increased risk for locally advanced disease as well as subsequent disease recurrence, and cancer-specific and all-cause mortality. These data suggest that serum NLR may be a useful prognostic marker for preoperative patient risk stratification, including consideration for neoadjuvant therapy and clinical trial enrollment.

Original languageEnglish (US)
Pages (from-to)1157-1164
Number of pages8
JournalEuropean Urology
Volume66
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Cystectomy
Urinary Bladder
Neutrophils
Lymphocytes
Carcinoma
Mortality
Neoplasms
Neoadjuvant Therapy
Recurrence
Survival
Logistic Models
Odds Ratio
Urinary Bladder Neoplasms
Multivariate Analysis
Lymph Nodes
Clinical Trials
Inflammation

Keywords

  • Bladder cancer
  • Neutrophil lymphocyte ratio
  • Radical cystectomy
  • Urothelial cancer

ASJC Scopus subject areas

  • Urology

Cite this

Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. / Viers, Boyd R.; Boorjian, Stephen A.; Frank, Igor; Tarrell, Robert F.; Thapa, Prabin; Karnes, Robert Jeffrey; Thompson, R. Houston; Tollefson, Matthew K.

In: European Urology, Vol. 66, No. 6, 01.12.2014, p. 1157-1164.

Research output: Contribution to journalArticle

Viers, Boyd R. ; Boorjian, Stephen A. ; Frank, Igor ; Tarrell, Robert F. ; Thapa, Prabin ; Karnes, Robert Jeffrey ; Thompson, R. Houston ; Tollefson, Matthew K. / Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. In: European Urology. 2014 ; Vol. 66, No. 6. pp. 1157-1164.
@article{f830f600e6a748e19826318c3cb8bf14,
title = "Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy",
abstract = "Background Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation that has been associated with adverse survival in a variety of malignancies. However, the relationship between NLR and oncologic outcomes following radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) has not been well studied.Design, setting, and participants We identified 899 patients who underwent RC without neoadjuvant therapy at our institution between 1994 and 2005 and who had a pretreatment NLR.Outcome measurements and statistical analysis Preoperative NLR (within 90 d prior to RC) was recorded. Recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard and logistic regression models were used to analyze the association of NLR with clinicopathologic outcomes.Results and limitations Median postoperative follow-up was 10.9 yr (interquartile range: 8.3-13.9 yr). Higher preoperative NLR was associated with significantly increased risks of pathologic, extravesical tumor extension (odds ratio [OR]: 1.07; p = 0.03) and lymph node involvement (OR: 1.09; p = 0.02). Univariately, 10-yr cancer-specific survival was significantly worse among patients with a preoperative NLR (≥2.7 [51{\%}] vs <2.7 [64{\%}]; p < 0.001). Moreover, on multivariate analysis, increased preoperative NLR was independently associated with greater risks of disease recurrence (hazard ratio [HR]: 1.04; p = 0.02), death from bladder cancer (HR: 1.04; p = 0.01), and all-cause mortality (HR: 1.03; p = 0.01).Conclusions Elevated preoperative NLR among patients undergoing RC is associated with significantly increased risk for locally advanced disease as well as subsequent disease recurrence, and cancer-specific and all-cause mortality. These data suggest that serum NLR may be a useful prognostic marker for preoperative patient risk stratification, including consideration for neoadjuvant therapy and clinical trial enrollment.",
keywords = "Bladder cancer, Neutrophil lymphocyte ratio, Radical cystectomy, Urothelial cancer",
author = "Viers, {Boyd R.} and Boorjian, {Stephen A.} and Igor Frank and Tarrell, {Robert F.} and Prabin Thapa and Karnes, {Robert Jeffrey} and Thompson, {R. Houston} and Tollefson, {Matthew K.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.eururo.2014.02.042",
language = "English (US)",
volume = "66",
pages = "1157--1164",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy

AU - Viers, Boyd R.

AU - Boorjian, Stephen A.

AU - Frank, Igor

AU - Tarrell, Robert F.

AU - Thapa, Prabin

AU - Karnes, Robert Jeffrey

AU - Thompson, R. Houston

AU - Tollefson, Matthew K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation that has been associated with adverse survival in a variety of malignancies. However, the relationship between NLR and oncologic outcomes following radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) has not been well studied.Design, setting, and participants We identified 899 patients who underwent RC without neoadjuvant therapy at our institution between 1994 and 2005 and who had a pretreatment NLR.Outcome measurements and statistical analysis Preoperative NLR (within 90 d prior to RC) was recorded. Recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard and logistic regression models were used to analyze the association of NLR with clinicopathologic outcomes.Results and limitations Median postoperative follow-up was 10.9 yr (interquartile range: 8.3-13.9 yr). Higher preoperative NLR was associated with significantly increased risks of pathologic, extravesical tumor extension (odds ratio [OR]: 1.07; p = 0.03) and lymph node involvement (OR: 1.09; p = 0.02). Univariately, 10-yr cancer-specific survival was significantly worse among patients with a preoperative NLR (≥2.7 [51%] vs <2.7 [64%]; p < 0.001). Moreover, on multivariate analysis, increased preoperative NLR was independently associated with greater risks of disease recurrence (hazard ratio [HR]: 1.04; p = 0.02), death from bladder cancer (HR: 1.04; p = 0.01), and all-cause mortality (HR: 1.03; p = 0.01).Conclusions Elevated preoperative NLR among patients undergoing RC is associated with significantly increased risk for locally advanced disease as well as subsequent disease recurrence, and cancer-specific and all-cause mortality. These data suggest that serum NLR may be a useful prognostic marker for preoperative patient risk stratification, including consideration for neoadjuvant therapy and clinical trial enrollment.

AB - Background Pretreatment neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation that has been associated with adverse survival in a variety of malignancies. However, the relationship between NLR and oncologic outcomes following radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) has not been well studied.Design, setting, and participants We identified 899 patients who underwent RC without neoadjuvant therapy at our institution between 1994 and 2005 and who had a pretreatment NLR.Outcome measurements and statistical analysis Preoperative NLR (within 90 d prior to RC) was recorded. Recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard and logistic regression models were used to analyze the association of NLR with clinicopathologic outcomes.Results and limitations Median postoperative follow-up was 10.9 yr (interquartile range: 8.3-13.9 yr). Higher preoperative NLR was associated with significantly increased risks of pathologic, extravesical tumor extension (odds ratio [OR]: 1.07; p = 0.03) and lymph node involvement (OR: 1.09; p = 0.02). Univariately, 10-yr cancer-specific survival was significantly worse among patients with a preoperative NLR (≥2.7 [51%] vs <2.7 [64%]; p < 0.001). Moreover, on multivariate analysis, increased preoperative NLR was independently associated with greater risks of disease recurrence (hazard ratio [HR]: 1.04; p = 0.02), death from bladder cancer (HR: 1.04; p = 0.01), and all-cause mortality (HR: 1.03; p = 0.01).Conclusions Elevated preoperative NLR among patients undergoing RC is associated with significantly increased risk for locally advanced disease as well as subsequent disease recurrence, and cancer-specific and all-cause mortality. These data suggest that serum NLR may be a useful prognostic marker for preoperative patient risk stratification, including consideration for neoadjuvant therapy and clinical trial enrollment.

KW - Bladder cancer

KW - Neutrophil lymphocyte ratio

KW - Radical cystectomy

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84909943000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909943000&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2014.02.042

DO - 10.1016/j.eururo.2014.02.042

M3 - Article

C2 - 24630414

AN - SCOPUS:84909943000

VL - 66

SP - 1157

EP - 1164

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -